Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence
Following new scientific insights, initial management for patients with high-risk nonmetastatic prostate cancer has changed considerably and rapidly over the last few years. Several clinical and pathologic variables should be taken into account when deciding the best treatment choice for those patie...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-03-01
|
| Series: | Therapeutic Advances in Urology |
| Online Access: | https://doi.org/10.1177/1756287217697661 |
| _version_ | 1828432841933848576 |
|---|---|
| author | Fouad Aoun Ali Bourgi Elias Ayoub Elie El Rassy Roland van Velthoven Alexandre Peltier |
| author_facet | Fouad Aoun Ali Bourgi Elias Ayoub Elie El Rassy Roland van Velthoven Alexandre Peltier |
| author_sort | Fouad Aoun |
| collection | DOAJ |
| description | Following new scientific insights, initial management for patients with high-risk nonmetastatic prostate cancer has changed considerably and rapidly over the last few years. Several clinical and pathologic variables should be taken into account when deciding the best treatment choice for those patients. These variables are summarized and discussed in detail. High radiation doses to the prostate are essential to achieve good local control in patients with high-risk nonmetastatic disease. Addition of androgen deprivation therapy (ADT) to radiation therapy has significantly improved overall survival and cancer-specific survival compared with radiation therapy alone without significantly increasing toxicity. Long-term neo(adjuvant) ADT (2–3 years) to radiation therapy significantly improved cancer-specific survival compared with short-term ADT (4–6 months). Radical prostatectomy with extended pelvic lymph node dissection is considered a reasonable option in experienced hands. ADT alone is an inappropriate treatment option for patients with high-risk nonmetastatic disease. Management decisions for these patients should be discussed by a multidisciplinary team. |
| first_indexed | 2024-12-10T18:26:44Z |
| format | Article |
| id | doaj.art-5a6284e7ad084298ac7b17e46146e8cf |
| institution | Directory Open Access Journal |
| issn | 1756-2872 1756-2880 |
| language | English |
| last_indexed | 2024-12-10T18:26:44Z |
| publishDate | 2017-03-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Urology |
| spelling | doaj.art-5a6284e7ad084298ac7b17e46146e8cf2022-12-22T01:38:04ZengSAGE PublishingTherapeutic Advances in Urology1756-28721756-28802017-03-01910.1177/1756287217697661Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidenceFouad AounAli BourgiElias AyoubElie El RassyRoland van VelthovenAlexandre PeltierFollowing new scientific insights, initial management for patients with high-risk nonmetastatic prostate cancer has changed considerably and rapidly over the last few years. Several clinical and pathologic variables should be taken into account when deciding the best treatment choice for those patients. These variables are summarized and discussed in detail. High radiation doses to the prostate are essential to achieve good local control in patients with high-risk nonmetastatic disease. Addition of androgen deprivation therapy (ADT) to radiation therapy has significantly improved overall survival and cancer-specific survival compared with radiation therapy alone without significantly increasing toxicity. Long-term neo(adjuvant) ADT (2–3 years) to radiation therapy significantly improved cancer-specific survival compared with short-term ADT (4–6 months). Radical prostatectomy with extended pelvic lymph node dissection is considered a reasonable option in experienced hands. ADT alone is an inappropriate treatment option for patients with high-risk nonmetastatic disease. Management decisions for these patients should be discussed by a multidisciplinary team.https://doi.org/10.1177/1756287217697661 |
| spellingShingle | Fouad Aoun Ali Bourgi Elias Ayoub Elie El Rassy Roland van Velthoven Alexandre Peltier Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence Therapeutic Advances in Urology |
| title | Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence |
| title_full | Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence |
| title_fullStr | Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence |
| title_full_unstemmed | Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence |
| title_short | Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence |
| title_sort | androgen deprivation therapy in the treatment of locally advanced nonmetastatic prostate cancer practical experience and a review of the clinical trial evidence |
| url | https://doi.org/10.1177/1756287217697661 |
| work_keys_str_mv | AT fouadaoun androgendeprivationtherapyinthetreatmentoflocallyadvancednonmetastaticprostatecancerpracticalexperienceandareviewoftheclinicaltrialevidence AT alibourgi androgendeprivationtherapyinthetreatmentoflocallyadvancednonmetastaticprostatecancerpracticalexperienceandareviewoftheclinicaltrialevidence AT eliasayoub androgendeprivationtherapyinthetreatmentoflocallyadvancednonmetastaticprostatecancerpracticalexperienceandareviewoftheclinicaltrialevidence AT elieelrassy androgendeprivationtherapyinthetreatmentoflocallyadvancednonmetastaticprostatecancerpracticalexperienceandareviewoftheclinicaltrialevidence AT rolandvanvelthoven androgendeprivationtherapyinthetreatmentoflocallyadvancednonmetastaticprostatecancerpracticalexperienceandareviewoftheclinicaltrialevidence AT alexandrepeltier androgendeprivationtherapyinthetreatmentoflocallyadvancednonmetastaticprostatecancerpracticalexperienceandareviewoftheclinicaltrialevidence |